Its top holdings include Questcor Pharmaceuticals (QCOR), Allergan (AGN) and Akorn (AKRX). “Most of the holdings are known companies, though,” Mishra said. Buy Generic Drugmakers Before They Take Off. The market has been on fire lately, but one group that hasn’t participated is generic drugmakers. Eldorado Gold (NYSE:EGO) and China Natural Resources (Nasdaq:CHNR) are both small-cap basic materials companies, but which is the superior stock?

Why Is the Stock Market Up Today Only 33 Points? MoneyMorning.com Report Why is the stock market up today ? Here's why the stock market rose, as well as a look at earnings reports, the top stock market news, and stocks to watch based on… TearLab Corporation (TEAR) Jumps: Stock Rises 7.2% - Tale of the Tape TearLab Corporation ( TEAR ) was a big mover last session, as the company saw its shares rise over 7% on the day. UMB Financial Q2 Earnings in Line with Estimates, Rises Y/Y - Analyst Blog UMB Financial Corporation 's ( UMBF ) second quarter 2014 earnings per share came in at 76 cents, in line with the Zacks Consensus Estimate. CaesarStone (CSTE): Moving Average Crossover Alert CaesarStone Sdot Yam Ltd. ( CSTE ) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. The ever popular onepage Snapshot reports are generated for virtually every single Zacks Ranked stock. And you don t need to know if the stock price used be higher or lower in past.

11/11/2011 · Akorn, Inc. makes multisource and branded pharmaceuticals. The company specializes in diagnostics and therapeutic products, hospital drugs and injectable

Options Traders Expect Huge Moves in Akorn (AKRX) Stock Zacks Apr-12-19 03:30PM LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akorn, Inc. The company has an expected earnings growth rate of 41.5% for the current year. The Zacks Consensus Estimate for the current year has improved 1.1% over the last 30 days. The stock has surged 40.9% year to date. 5 Stocks Set to Double. Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Zacks Investment Research upgraded shares of Akorn (NASDAQ:AKRX) from a hold rating to a buy rating in a research note published on Thursday morning, Zacks.com reports. They currently have $4.75 price objective on the stock. Zacks Investment Research upgraded shares of Akorn (NASDAQ:AKRX) from a hold rating to a buy rating in a research note released on Thursday morning, Zacks.com reports. Zacks Investment Research currently has $5.25 price objective on the stock.

Akorn (NASDAQ:AKRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday, Zacks.com reports. According to Zacks, “Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals.

5/24/1991 · Is Akorn, Inc. (AKRX) Going To Burn These Hedge Funds ? Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). AKRX, Akorn Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Get breaking news and analysis on Akorn, Inc. (AKRX) stock, price quote and chart, trading and investing tools. 8/27/2018 · AKRX sticks out from AMPH in both our Zacks Rank and Style Scores models, so value investors will likely feel that AKRX is the better option right now. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report. Akorn, Inc. (AKRX): Free Stock Analysis Akorn (NASDAQ:AKRX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, Zacks.com reports. The brokerage presently has a $4.75 target price on the stock. Stock quote for Akorn, Inc. Common Stock Common Stock (AKRX) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq.

In the past year, the stock has hit a 52-week low of $29.76 and Wednesday, June 13, 2012 Medicis Pharmaceutical (NYSE:MRX) closed Tuesday

Crowdsourced stock and analyst ratings and analysis for Infinity Property and Casualty Corporation ($IPCC) from the leading crowdsourced stock rating platform. Eldorado Gold (NYSE:EGO) and China Natural Resources (Nasdaq:CHNR) are both small-cap basic materials companies, but which is the superior stock? Zacks Rank #5 Additions for Tuesday - Tale of the Tape Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today Abaxis Inc ( ABAX )AK Steel Holding Corporation ( AKS )American Capital Mortgage Investment Crp ( MTGE )Atlantic… eVal develop dynamic web-based apps and valuation tools. This page provides a list of peer compay data, include corporation or group name and equity ticker.

In the past year, the stock has hit a 52-week low of $29.76 and Wednesday, June 13, 2012 Medicis Pharmaceutical (NYSE:MRX) closed Tuesday

Find the latest Akorn, Inc. (AKRX) stock quote, history, news and other vital The Zacks Analyst Blog Highlights: Forterra, Barrett Business, Chuy's, Akorn and  28 Nov 2019 Akorn (AKRX) might move higher on growing optimism about its earnings Here is where the tried-and-tested Zacks Rank stock-rating system  Dec-19-19 09:26AM, Akorn Enters Oversold Territory Zacks -11.87%. Dec-18-19 02:52PM, Akorn's stock extends plunge toward record low after disclosing it  AKRX | Complete Akorn Inc. stock news by MarketWatch. View real-time stock AKRX U.S.: Nasdaq.. stock. Dec. 19, 2019 at 9:26 a.m. ET on Zacks.com 

2/8/2012 · AKRX earnings leapt from a 28 cent loss to a 22 cent profit from FY2009 to FY2010. Akorn is expected to earn $0.29 in FY2011 according to the Zacks Consensus Estimate. Earnings Estimates Since AKRS is a small cap, only 2 analysts cover the stock, but both raised estimates higher for the coming quarters as well as FY2011 and FY2012 in the past Akorn (NASDAQ:AKRX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, Zacks.com reports. The firm presently has a $5.50 price target on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 20.61% from the stock’s previous View the latest AKRX stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of AKORN, INC.. View live AKORN INC chart to track its stock's price action. Find market predictions, AKRX financials and market news.